Abstract
The genetically modified Zika virus (oZIKV) represents an innovative oncolytic virotherapy platform based on rational genetic modifications that confer tumor selectivity and an improved safety profile, as demonstrated in previous experimental studies using relevant models of central nervous system (CNS) tumors (KAID et al., 2018; NOVAES et al., 2024). While the scientific maturity of the …